Episode Details

Dyadic Internationals 2025 earnings report shows a slight dip in revenue, but a surge in grant revenue from the Gates Foundation. The company posted a net loss, but has $8.6 million in cash on hand. Dyadic is shifting from development to commercial biotech products, launching recombinant human albumin and other products with partners. Sales are slow due to customer qualification, but partnerships are expanding reach. In food and nutrition, deals for alpha-lactalbumin and chymosin are in the works. Bioindustrial enzymes for biofuels are gaining traction in Asia, and biopharma grants support vaccine work. Dyadic expects recurring revenue this year from repeat orders and milestone payments, leveraging platforms for scalable growth.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/68d5851740d14cc2